Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | PPIA | P62937 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6644785 | 0.85 | MAPK1 (0.47) | MAPK1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6644570 | 0.79 | ALDH1A1 (0.39) | EPHX2EPHX1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4516474 | 0.72 | MAPK1 (0.49) | MAPK1ALDH1A1HPGDKDM4E | |
| SCHEMBL7645833 | 0.72 | HPGD (0.55) | EPHX2SMN1; SMN2ALDH1A1L3MBTL1HPGD | |
| SCHEMBL8044966 | 0.71 | CES2 (0.43) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6643313 | 0.70 | CES2 (0.41) | KMT2AALDH1A1 | |
| SCHEMBL6646405 | 0.70 | HPGD (0.43) | MAPK1EPHX2EPHX1MEN1KMT2A | |
| SCHEMBL6647834 | 0.70 | MAPK1 (0.56) | MAPK1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13332426 | 0.67 | NPC1 (0.60) | EPHX1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL4514409 | 0.67 | POLB (0.50) | MAPK1EPHX2EPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401830-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
| WO-2002102793-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | MAPK1 544/4885EPHX2 4469/4885EPHX1 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.